Related references
Note: Only part of the references are listed.Novel Avian Influenza A Virus Infections of Humans
Timothy M. Uyeki et al.
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2019)
Co-stimulation With TLR7 Agonist Imiquimod and Inactivated Influenza Virus Particles Promotes Mouse B Cell Activation, Differentiation, and Accelerated Antigen Specific Antibody Production
Can Li et al.
FRONTIERS IN IMMUNOLOGY (2018)
TLR7/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth
David J. Dowling et al.
JCI INSIGHT (2017)
Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial
Ivan Fan-Ngai Hung et al.
LANCET INFECTIOUS DISEASES (2016)
Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response A Randomized Clinical Trial
Lisa A. Jackson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands as Influenza Virus Vaccine Adjuvants Induce Rapid, Sustained, and Broadly Protective Responses
Peter H. Goff et al.
JOURNAL OF VIROLOGY (2015)
Intradermal vaccination using the novel microneedle device MicronJet600: Past, present, and future
Yotam Levin et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2015)
Toll-Like Receptor 7 Agonist Imiquimod in Combination with Influenza Vaccine Expedites and Augments Humoral Immune Responses against Influenza A(H1N1) pdm09 Virus Infection in BALB/c Mice
Anna J. X. Zhang et al.
CLINICAL AND VACCINE IMMUNOLOGY (2014)
Immunogenicity of Intradermal Trivalent Influenza Vaccine With Topical Imiquimod: A Double Blind Randomized Controlled Trial
Ivan F. N. Hung et al.
CLINICAL INFECTIOUS DISEASES (2014)
Serological Responses to an Avian Influenza A/H7N9 Vaccine Mixed at the Point-of-Use With MF59 Adjuvant A Randomized Clinical Trial
Mark J. Mulligan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Direct Comparison of an Inactivated Subvirion Influenza A Virus Subtype H5N1 Vaccine Administered by the Intradermal and Intramuscular Routes
Shital M. Patel et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
A Randomized Clinical Trial of an Inactivated Avian Influenza A (H7N7) Vaccine
Robert B. Couch et al.
PLOS ONE (2012)
The Innate Immune Response, Clinical Outcomes, and Ex Vivo HCV Antiviral Efficacy of a TLR7 Agonist (PF-4878691)
M. D. Fidock et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Qualification of the Hemagglutination Inhibition Assay in Support of Pandemic Influenza Vaccine Licensure
Diana L. Noah et al.
CLINICAL AND VACCINE IMMUNOLOGY (2009)
An exploratory study of systemic administration of the Toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma
Reinhard Dummer et al.
CLINICAL CANCER RESEARCH (2008)
First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agionist, to activate innate immune responses in patients with advanced cancer
Arkadiusz Z. Dudek et al.
CLINICAL CANCER RESEARCH (2007)
Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine
JJ Treanor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
HIV Gag protein conjugated to a toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates
U Wille-Reece et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Plasmacytoid dendritic cell precursors/type I interferon-producing cells sense viral infection by Toll-like receptor (TLR) 7 and TLR9
T Ito et al.
SPRINGER SEMINARS IN IMMUNOPATHOLOGY (2005)
Share Paper
